Rapamycin vs. Metformin: What a New Vertebrate Meta-Analysis Actually Found

Dietary restriction — eating meaningfully less without malnutrition — is the most reproducible lifespan intervention in biology. The trouble is human. Sustained caloric restriction is brutally hard to maintain, and for women in midlife and beyond it carries its own risks around bone, muscle, and mood. So the search has long been for a molecule that flips the same biological switches without requiring anyone to push the plate away.

That's where rapamycin and metformin entered the chat. Both touch pathways — mTOR for rapamycin, AMPK and mitochondrial signaling for metformin — that overlap with the cellular response to eating less. But until now, the actual question, how does each compare to dietary restriction itself in vertebrates?, hadn't been answered head-to-head across the literature.

The new meta-analysis by Ivimey-Cook, Sultanova, and Maklakov in Aging Cell pooled 911 effect sizes from 167 papers covering eight vertebrate species. It is the most disciplined attempt yet to settle the comparison.

Three findings stand out. First, dietary restriction robustly extended lifespan across the vertebrate dataset, holding up across different ways of measuring lifespan and across different DR methodologies. That is reassuring rather than surprising — it confirms the benchmark.

Second, rapamycin produced a significant lifespan extension; metformin did not. In a field where both drugs are often invoked in the same breath, that is a meaningful divergence. It suggests that, at the vertebrate level, rapamycin is the molecule that more closely tracks the biology of eating less.

Third, sex didn't seem to consistently change the answer. Across treatments and across the way lifespan was reported, the authors did not find a reliable male–female split. For a literature that has historically over-relied on male mice, this is a small but useful note.

Here is where the language has to slow down. The authors themselves flag high heterogeneity and significant publication bias across treatments. Translated: studies varied widely in design and dose, and the published literature likely overrepresents positive results. The headline still survives those caveats — that is part of what makes meta-analysis useful — but it survives moderately, not triumphantly.

The results were also sensitive to how lifespan was reported (means versus medians, log-response framings). That doesn't erase the rapamycin signal, but it does mean a careful reader should resist any version of this story that reads as rapamycin extends life, full stop.

And then there is the species gap. Vertebrates include fish, rodents, and a handful of others — not humans. The conclusion the authors actually draw is bounded: rapamycin and dietary restriction confer comparable lifespan extension across a broad range of vertebrates. That is a statement about biology, not a prescription about you.

For readers whose physicians are already discussing geroprotectors, the practical reframe is this: the vertebrate evidence base now leans more strongly toward rapamycin as the molecule that imitates dietary restriction's lifespan effect. Metformin's case for general longevity use — as opposed to its well-established role in type 2 diabetes — looks weaker in this dataset than the cultural conversation has implied.

That is not the same as saying rapamycin is safe, appropriate, or beneficial for any individual woman in her fifties, sixties, or seventies. Rapamycin's human use to date is mostly in transplant medicine and oncology, at doses and schedules unlike anything contemplated for longevity. Its real-world side-effect profile in healthy adults, taken for decades, is genuinely not known. The honest position is curiosity with restraint.

For everyone else — which is most of us — the more durable takeaway sits upstream of the pills. Dietary restriction's lifespan signal is the most robust in the dataset, and the levers that approximate it without medication (protein-adequate caloric moderation, time-restricted eating windows under clinical guidance, resistance training to protect muscle and bone) remain the closest thing the field has to a free lunch. They are also, not coincidentally, the things a thoughtful clinician will discuss before any prescription is written.

What a meta-analysis like this really does is reset the prior. For years, rapamycin and metformin have been spoken of as siblings in the geroprotector conversation. After this paper, they look less like siblings and more like cousins with very different family resemblances to dietary restriction. That matters for which human trials deserve funding, which questions deserve our attention, and which claims — from clinics, podcasters, and supplement sellers — deserve a harder look.

The field is not done. Human outcomes data is what will ultimately matter, and we don't have it yet at the scale this question requires. But the vertebrate picture is now sharper than it was a year ago, and sharper is what serious readers came here for.